Forgot Password?
Return to Course Listing

CME: Advancing Treatment Strategies in Multiple Myeloma (MM) Drug Therapy


Activity Description / Statement of Need:

In this online CME self-learning program:


Multiple myeloma (MM) is a hematologic malignancy of the lymphocytes. All cases are marked by monoclonal gammopathy, and while the true cause is unknown, associated factors are thought to include: radiation, genetics, viral infections, and the human immunodeficiency virus.(1) While MM only makes up about 1% of all cancers, it the most common of the blood cancers, and its incidence has risen from the lower end of 22,000 cases per year five years age to an estimated 26,850 in 2015; mortality rates have stayed consistent at approximately 11,000 per year. The peak incidence age of MM is at about 70 years of age, and the disease occurs twice as commonly in African Americans as it does in whites. Helping the clinician discern the role of each of the first-line and more novel therapies, including monoclonal antibodies and proteasome, deacetylase, and 3 serine/threonine protein kinase inhibitor therapies – among others – based on the most up-to-date research merits continuing education programming in MM.




Faculty introduction, disclosures

Introduction content [Learning Objective #1]

  • Statistics and prognosis: Overall survival
  • Pathophysiology: germinal center plasma cells, B cell precursor, clonal evolution theory, bone marrow microenvironment, dysregulation of the cyclin D / retinoblastoma pathway
  • Most recent IMWG diagnostic criteria, smoldering myeloma, revised ISS, cytogenetic abnormality highlights

Updates in treatment in patients with MM [Learning Objectives #2, 3, & 4]

  • Transplant eligibility, induction, regimens, and related clinical trial updates
  • Evaluation of treatment response
  • Relapsed myeloma
  • Present pharmacotherapy and update in clinical trial evidence
  • Investigational agents
  • Principles in supportive care
  • Clinical challenges including complication management
  • The role of the clinician as educator
  • Patient case(s)

Summary, conclusions, and best practice recap

Target Audience:

Hematologists and oncologists; physician assistants, nurse practitioners, nurses, and pharmacists who practice in oncology; and any other healthcare professionals with an interest in or who clinically encounter patients with MM.

This program is supported by educational grants from AMGEN.

Release Date: November 02, 2017 -- Expiration Date: November 02, 2019

Faculty: Ravi Vij, MD MBA


Learning Objectives

By the end of the session the participant will be able to:

  • Recall updates in the staging, prognosis, and diagnosis of MM.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: treatment modalities and the recent clinical trial evidence supporting them.
  • Distinguish between the most appropriate treatment approaches to MM and apply them to practice, taking into account the following: evidence-based treatment guidelines, algorithms, and expert opinion.
  • Summarize the risk-benefit profiles of current and emerging therapies for the treatment of MM.



Faculty Disclosure and Resolution of COI

 As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


Faculty Disclosure:  Ravi Vij, MD, Professor of Medicine, Washington University School of Medicine, Section of Stem Cell Transplant and Leukemia, St. Louis, Missouri, has received grants from Amgen and Takeda, and serves as a consultant to Jazz, Abbvie, Karyopharma Amgen, Takeda, Celgene, BMS, and Janssen.


Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant financial disclosures.


Commercial Support Disclosure: This program is supported by educational grants from AMGEN.


  • Read the learning objectives above
  • Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
  • View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
  • Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
  • Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.

Cultural/Linguistic Competence & Health Disparities

System Requirements

Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh

*Required to view Printable PDF Version

Perform Pre-Test (optional)

Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

Additional Courses That Are Related To This Activity

Multiple Myeloma Pharmacotherapy: Therapeutic Updates, Best Practices, and Emerging Treatment Options

Diffuse Large B-Cell Lymphoma (DLBCL): Therapeutic Updates and Best Practices

Acute Lymphoblastic Leukemia (ALL): Highlights from the 2016 American Society of Hematology (ASH 2016): Take-Aways, Emerging Practice Changes, and Barriers to their Implementation

Advancing Treatment Strategies in Acute Lymphoblastic Leukemia (ALL) Drug Therapy